MTOR and hepatocellular carcinoma: Treatment also downregulated the PI3 K/Akt, NF-κB, and mammalian target of rapamycin (mTOR) signaling pathways, as well as the migration and invasion of hepatocellular carcinoma (HCC) cells [35].